Z-206 Phase III Clinical Trial - Investigation on the remission-maintaining effect in patients with Crohn's disease in remission phase
Phase 3
- Conditions
- Patients with Crohn's disease in remission phase
- Registration Number
- JPRN-jRCT2080220190
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with Crohn's disease in remission phase who are defined to show CDAI of less than 150, and whose lesion is mainly observed at the end of ileum or lower part.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence rate
- Secondary Outcome Measures
Name Time Method